What the business is, and whether it's a good one at a fair price.
A Pharmaceuticals & Biotechnology company listed on NSE and BSE, reporting revenue of ₹8,608 Cr over the trailing twelve months.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from JUBILANT PHARMOVA LTD's filed financials and exchange disclosures
JUBILANT PHARMOVA LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol JUBLPHARMA.
Yes. Over the trailing twelve months JUBILANT PHARMOVA LTD reported a net profit of ₹351 Cr on revenue of ₹8,608 Cr.
Yes. The dividend yield is 0.49% at the current price. It paid out 20% of its profit as dividend in FY26.
No. Debt stands at 0.45× equity, and it carries net debt of ₹1,952 Cr. That is lower than 20% of its 171 Pharmaceuticals peers.
On trailing P/E, JUBILANT PHARMOVA LTD ranks 127 of 169 in Pharmaceuticals — cheaper than 25% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session JUBILANT PHARMOVA LTD moves 1.14% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by JUBILANT PHARMOVA LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
